UPDATE: Lilly shares slide after FDA delay
Investors in Eli Lilly and Co. showed displeasure this morning in the decision announced late yesterday that the U.S. Food and Drug Administration will extend its review of Lilly’s prasugrel drug by three months. Shares in the Indianapolis pharmaceutical company fell 2 percent, to $46.63 – a 52-week low. The FDA’s decision on the highly […]